摘要
乳腺癌是女性最常见的恶性肿瘤之一，近年来发病率逐年增高，内分泌治疗是乳腺癌最重要的治疗方法之一。第三代芳香化酶抑制剂的研发使用是当前乳腺癌内分泌治疗的重大进展。他莫昔芬（TAM）曾是早期乳腺癌辅助内分泌治疗的金标准药物，但现在它正日益受到第三代芳香化酶抑制剂的挑战，正是由于第三代芳香化酶抑制剂疗效的显著性和副反应的易控性，它正取代TAM的地位，被一些国家及国际临床指南推荐为绝经后雌、孕激素受体阳性患者的首选治疗药物。现对乳腺癌芳香化酶抑制剂治疗新进展作一综述。
出处
《浙江医学》
CAS
2008年第3期301-303,共3页
Zhejiang Medical Journal
参考文献18
-
1Perez E A. Appraising adjuvant aromatase inhibitor therapy[J]. Oncologist, 2006, 11 ( 10 ):1058 - 1069.
-
2Conte P, Frassoldati A. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective[J]. Breast J, 2007, 13(1) 28-35.
-
3The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial[J]. Lancet, 2002, 359:2131-2139.
-
4The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer[J]. Cancer. 2003. 98:1802-1810.
-
5Dowsett M Analysis of time to recurrence in the ATAC (Arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status[J]. Breast Cancer Res Treat, 2003,82:S7.
-
6Ellis M J, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase Ⅲ randomized trial[J]. J Clin Oncol. 2001.19:3808-3816.
-
7Goss P E, Ingle J N, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer[J]. N Engl J Med, 2003, 349:1793-1802.
-
8Thurlimann B, Keshaviah A. Breast International Group (BIG) 1-98 Collaborative Group.A comparison of letrozole and tamoxifen in postmenopausal women with eady breast cancer[J]. N Engl J Med, 2006,354(20):2200.
-
9Ingle J N, Tu D, Pater J L, et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial [J]. Breast Cancer Res Treat 2006. 99:295-300.
-
10Coombes R C, Hall E, Gibson L J, et al. A randomized trial of exernestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer[J]. N Engl J Med, 2004, 350:1081-1092.
同被引文献9
-
1江敏,崔鹏,于涛,杨帆,汤杰.3β-羟基雄甾-4-烯-6,17-二酮的合成[J].应用化学,2006,23(12):1422-1424. 被引量：2
-
2Numazawa M,Tsuji M,Mutsumi A.J Steroid Biochem[J],1987,28:337.
-
3Lbler L,Slma K,om F.Coll Czech Chem Commun[J],1968,33(2):226.
-
4Deive N,Rodriguez J,Jinenez C.J Med Chem[J],2001,44(2):612.
-
5Corey E J,Suggs W.Tetrahedron Lett[J],1975,31:2647.
-
6Nagia A,Anthony A.Synth Commun[J],1996,26:225.
-
7Hunter A C,Priest S M.Steroids[J],2006,71:30.
-
8刘君,姜淮芜.芳香化酶抑制剂治疗乳腺癌的临床研究进展[J].中国现代普通外科进展,2007,10(6):510-512. 被引量：1
-
9崔建国,曾陇梅,苏镜娱,彭文烈,徐安龙.多羟基甾醇的合成及其结构与抗肿瘤细胞活性关系研究[J].高等学校化学学报,2000,21(9):1399-1404. 被引量：16
-
1张斌.乳腺癌新辅助内分泌治疗[J].中国癌症杂志,2006,16(9):689-692. 被引量：9
-
2蔡凤林,周士福.胃癌淋巴结转移误诊为乳腺癌转移[J].临床误诊误治,2008,21(8):76-76.
-
3王巧莲,吴元赭.第三代芳香化酶抑制剂与子宫内膜癌的关系[J].中国妇幼保健,2012,27(22):3525-3526.
-
4周波,杨德启,刘淼,谢菲.乳腺癌术后辅助内分泌治疗策略[J].中国全科医学（医生读者版）,2013,16(11):51-54.
-
5王丰莲,杨亚明.第三代芳香化酶抑制剂治疗绝经后乳腺癌肺转移疗效观察[J].中国热带医学,2008,8(3):410-411. 被引量：2
-
6王俊,王建中,张长春,成家辉,杨勇,罗毅.培美曲塞二钠联合洛铂或顺铂在晚期肺腺癌中的疗效观察[J].实用癌症杂志,2016,31(2):239-241. 被引量：9
-
7许波,田怀杲.乳腺癌辅助内分泌治疗的研究进展[J].蚌埠医学院学报,2013,38(10):1381-1383.
-
8徐兵河.第三代芳香化酶抑制剂在乳腺癌术后辅助治疗中的应用进展[J].中国癌症杂志,2005,15(1):72-74. 被引量：2
-
9王万忠,种瑞峰,郑敏,齐恒.第三代芳香化酶抑制剂在绝经后乳腺癌新辅助内分泌治疗中的应用[J].中国医学创新,2011,8(22):192-195. 被引量：2
-
10毛启新,张乐,张敏,张瑾.戈舍瑞林在绝经前乳腺癌内分泌治疗中对卵巢功能抑制作用的前瞻性临床研究[J].中国癌症杂志,2010,20(1):73-75. 被引量：4
